CA1
ENSG00000133742
Target class
Enzyme
Chromosome
8
Approved drugs
6
Clinical candidates (approved and in development)
8
- Approved drugs
- 6
- Clinical candidates (approved and in development)
- 8
- Chemical probe available
- No
- Other names
- Car1
- Target name
- CA1
- Gene name
- Carbonic anhydrase 1
- Gene symbol
- CA1
- Protein name
- Carbonic anhydrase 1 (EC 4.2.1.1) (Carbonate dehydratase I) (Carbonic anhydrase B) (CAB) (Carbonic anhydrase I) (CA-I) (Cyanamide hydratase CA1) (EC 4.2.1.69)
- Gene biotype
- Protein coding
- Gene family
- Carbonic anhydrases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 4
- Highest tissue expression
- 87.47
- Tissue specificity (Gini)
- 0.937
- Tissue specificity (tau)
- 0.989
- KEGG gene identifiers
- hsa:759
- Protein interaction confidence
- 0.797
- Protein interaction partners
- 12
- R-HSA-1237044
- R-HSA-1247673
- R-HSA-1475029
- R-HSA-8950505
- End position
- 85379014
- Start position
- 85327608
- Chromosome
- 8
- Strand
- Reverse
- Cytoplasm .
- Tissue specificity (tau)
- 0.989066
- Expression inequality (Gini)
- 0.936644
Expression in transcripts per million
- Colon - Transverse
- 87.47
- Whole Blood
- 40.01
- Spleen
- 3.99
- Lung
- 1
- Colon - Sigmoid
- 0.48
Expression in transcripts per million
- Colon - Transverse87.47
- Whole Blood40.01
- Spleen3.99
- Lung1
- Colon - Sigmoid0.48
- Liver0.3
- Fallopian Tube0.25
- Small Intestine - Terminal Ileum0.25
- Pituitary0.24
- Cervix - Ectocervix0.19
- Thyroid0.19
- Kidney - Cortex0.19
- Adipose - Visceral (Omentum)0.18
- Vagina0.14
- Brain - Substantia nigra0.13
- Brain - Spinal cord (cervical c-1)0.13
- Kidney - Medulla0.12
- Bladder0.12
- Brain - Cerebellum0.12
- Heart - Atrial Appendage0.11
- Brain - Hypothalamus0.11
- Breast - Mammary Tissue0.11
- Minor Salivary Gland0.1
- Artery - Coronary0.1
- Uterus0.1
And 29 more, listed on the interactive page.
- GO:0005829
- GO:0070062
- GO:0004064
- GO:0004089
- GO:0005515
- GO:0016836
- GO:0018820
Related records
Trials (182)
- A Combined Surgical and Medical Approach in Mild Sleep Apnea
- A Noninvasive Arterial Input Estimation Method for O-15 PET and Integrated PET/MR Scanning
- A Phase 3 Study of F14 for Management of Pain Following Total Knee Replacement
- A Randomized, Open-label Study on Helicobacter Pylori Eradication With Standard Triple Regimen Plus Acetazolamide
- A Short Term Open, Randomized Cross-over Trial Exploring the Effect of Carbonic Anhydrase Inhibition by Acetazolamide on Sleep Apnea Associated Hypertension and Vascular Dysfunction
- A Single-center Pilot Study Evaluating the Immediate Effects of Low-dose Acetazolamide on Respiratory Control in Subjects With Treatment Emergent Sleep Disordered Breathing
- A Trial of Acetazolamide Versus Placebo in Preventing Mountain Sickness During Rapid Ascent
- Acamprosate and Methazolamide for Essential Tremor
- Acetazolamide (AZ) for Management of Alkalosis in Bartter Syndrome
- Acetazolamide Add-On Therapy to OSA Surgery
- Acetazolamide and Exercise Performance at Altitude
- Acetazolamide as a Means to Mitigate Falling Ventilatory Drive and Drive-dependent OSA
- Acetazolamide Challenge With Perfusion in the Prediction of Cerebral Vasospasm
- Acetazolamide Efficacy in Ataxia in PMM2-CDG
- Acetazolamide Facilitates Ventilator Weaning
- Acetazolamide for Obstructive Sleep Apnea to Improve Heart Health
- Acetazolamide for Respiratory Failure in Combination With Metabolic Alkalosis
- Acetazolamide for the Prevention of High Altitude Illness: a Comparison of Dosing
- Acetazolamide for the Prevention of Post Operative CSF Leak
- Acetazolamide for Treating NPH in Shunt-candidates Patients
Drugs (8)
- Acetazolamide Carbonic anhydrase I inhibitor
- Acetazolamide sodium Carbonic anhydrase I inhibitor
- Dichlorphenamide Carbonic anhydrase I inhibitor
- Ethoxzolamide Carbonic anhydrase inhibitor
- Methazolamide Carbonic anhydrase I inhibitor
- Methocarbamol Carbonic anhydrase I inhibitor
- Polmacoxib Carbonic anhydrase I inhibitor
- Sulthiame Carbonic anhydrase inhibitor